Education
About Us
Working with TipRanks
Follow Us
ZyVersa Therapeutics (ZVSA)
OTHER OTC:ZVSA
Total Valuation
ZyVersa Therapeutics has a market cap or net worth of $2.00M. The enterprise value is $8.45M.
Market Cap$2.00M
Enterprise Value$8.45M
Share Statistics
ZyVersa Therapeutics has 7,935,921 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding7,935,921
Owned by Insiders11.03%
Owned by Institutions0.36%
Financial Efficiency
ZyVersa Therapeutics’s return on equity (ROE) is -1.11 and return on invested capital (ROIC) is -97461.45%.
Return on Equity (ROE)-1.11
Return on Assets (ROA)-456.98
Return on Invested Capital (ROIC)-97461.45%
Return on Capital Employed (ROCE)-975.31
Revenue Per Employee0.00
Profits Per Employee-1.34M
Employee Count7
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio―
PS Ratio0.00
PB Ratio0.14
Price to Fair Value<0.01
Price to FCF-9.53
Price to Operating Cash Flow-9.53
PEG Ratio>-0.01
Income Statement
In the last 12 months, ZyVersa Therapeutics had revenue of 0.00 and earned -9.41B in profits. Earnings per share was -848.03.
Revenue0.00
Gross Profit0.00
Operating Income-9.14B
Pretax Income-9.42B
Net Income-9.41B
EBITDA-9.14B
Earnings Per Share (EPS)-848.03
Cash Flow
In the last 12 months, operating cash flow was -4.85B and capital expenditures 0.00, giving a free cash flow of -4.85B billion.
Operating Cash Flow-4.85B
Free Cash Flow-4.85B
Free Cash Flow per Share-611.62
Dividends & Yields
ZyVersa Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.81
52-Week Price Change-94.15%
50-Day Moving Average0.54
200-Day Moving Average1.00
Relative Strength Index (RSI)33.40
Average Volume (3m)8.39M
Important Dates
ZyVersa Therapeutics upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
ZyVersa Therapeutics as a current ratio of 0.15, with Debt / Equity ratio of 0.11%
Current Ratio0.15
Quick Ratio0.15
Debt to Market Cap0.00
Net Debt to EBITDA<0.01
Interest Coverage Ratio-33.86K
Taxes
In the past 12 months, ZyVersa Therapeutics has paid -6.75M in taxes.
Income Tax-6.75M
Effective Tax Rate<0.01
Enterprise Valuation
ZyVersa Therapeutics EV to EBITDA ratio is >-0.01, with an EV/FCF ratio of -1.35.
EV to Sales0.00
EV to EBITDA>-0.01
EV to Free Cash Flow-1.35
EV to Operating Cash Flow-1.35
Balance Sheet
ZyVersa Therapeutics has $1.61B in cash and marketable securities with $0.00 in debt, giving a net cash position of -$1.61B billion.
Cash & Marketable Securities$1.61B
Total Debt$0.00
Net Cash-$1.61B
Net Cash Per Share-$203.07
Tangible Book Value Per Share-$0.91
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for ZyVersa Therapeutics is $20.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$20.00
Price Target Upside9900.00% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast99.39%